ReviewJournal of transplantation2016
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.
Review in Journal of transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study.World journal of transplantation · 2026Article
- Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.Cancers · 2024Article
- Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy.Journal of clinical medicine · 2023Article
- Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.International journal of clinical oncology · 2023Review
- Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.Seminars in nephrology · 2022Review
- Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patients-A Pilot Study.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- Current Status of Malignant Tumors after Organ Transplantation.BioMed research international · 2022Review
- Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma.Clinical and molecular hepatology · 2021Article
- Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors.Cancer management and research · 2021Review
- Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.International journal of molecular sciences · 2020Review
- From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment.Frontiers in immunology · 2020Review
- Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2019Observational
- Keratinocyte Carcinomas: Current Concepts and Future Research Priorities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk ofFrontiers in oncology · 2019Review
- Effect of mechanistic target of rapamycin inhibitors on postrenal transplantation malignancy: A nationwide cohort study.Cancer medicine · 2018Article
- Living donor liver transplantation prior to multiple myeloma treatment in a patient with hepatitis B-associated hepatocellular carcinoma and liver cirrhosis: a case report.Annals of surgical treatment and research · 2018Article
- Dermatological Complications After Solid Organ Transplantation.Clinical reviews in allergy & immunology · 2018Review
- Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma.Cancer management and research · 2018Article
- Basics and Art of Immunosuppression in Liver Transplantation.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancers. In kidney transplantation, evidence from registry studies indicates a lower rate of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.